Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001842952-23-000085
Filing Date
2023-11-09
Accepted
2023-11-09 16:04:33
Documents
52
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cntx-20230930.htm   iXBRL 10-Q 612411
2 EX-31.1 cntx2023-093010xqexhibit311.htm EX-31.1 10749
3 EX-31.2 cntx2023093010-qexhibit312.htm EX-31.2 10751
4 EX-32.1 cntx2023093010-qexhibit321.htm EX-32.1 6508
  Complete submission text file 0001842952-23-000085.txt   3456007

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntx-20230930.xsd EX-101.SCH 24913
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cntx-20230930_cal.xml EX-101.CAL 29155
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cntx-20230930_def.xml EX-101.DEF 96139
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntx-20230930_lab.xml EX-101.LAB 429999
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntx-20230930_pre.xml EX-101.PRE 253020
46 EXTRACTED XBRL INSTANCE DOCUMENT cntx-20230930_htm.xml XML 320384
Mailing Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103
Business Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103 267-225-7416
Context Therapeutics Inc. (Filer) CIK: 0001842952 (see all company filings)

IRS No.: 863738787 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40654 | Film No.: 231392228
SIC: 2834 Pharmaceutical Preparations